NASDAQ:PEPG PepGen (PEPG) Stock Price, News & Analysis $18.55 +0.53 (+2.94%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$17.63▼$18.9050-Day Range$13.49▼$18.5552-Week Range$3.72▼$18.90Volume124,231 shsAverage Volume148,824 shsMarket Capitalization$601.39 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get PepGen alerts: Email Address PepGen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside24.0% Upside$23.00 Price TargetShort InterestBearish2.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 7 Articles This WeekInsider TradingSelling Shares$844,269 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.87) to ($2.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.07 out of 5 starsMedical Sector619th out of 936 stocksPharmaceutical Preparations Industry286th out of 436 stocks 2.5 Analyst's Opinion Consensus RatingPepGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePepGen has only been the subject of 2 research reports in the past 90 days.Read more about PepGen's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.25% of the float of PepGen has been sold short.Short Interest Ratio / Days to CoverPepGen has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in PepGen has recently increased by 51.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPepGen does not currently pay a dividend.Dividend GrowthPepGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PEPG. Previous Next 2.4 News and Social Media Coverage News SentimentPepGen has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for PepGen this week, compared to 1 article on an average week.MarketBeat Follows2 people have added PepGen to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PepGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $844,269.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of PepGen is held by insiders.Percentage Held by Institutions58.01% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PepGen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PepGen are expected to grow in the coming year, from ($2.87) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PepGen is -5.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PepGen is -5.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPepGen has a P/B Ratio of 4.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about PepGen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About PepGen Stock (NASDAQ:PEPG)PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Read More PEPG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PEPG Stock News HeadlinesJuly 20, 2024 | insidertrades.comPepGen Inc. (NASDAQ:PEPG) Insider Michelle L. Mellion Sells 12,625 SharesJuly 19, 2024 | insidertrades.comPepGen Inc. (NASDAQ:PEPG) Insider Sells $59,315.52 in StockJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 27, 2024 | insidertrades.comInsider Selling: PepGen Inc. (NASDAQ:PEPG) Insider Sells 9,260 Shares of StockJuly 21, 2024 | investing.comPepGen's chief medical officer sells shares worth over $229kJuly 18, 2024 | americanbankingnews.comMichelle L. Mellion Sells 5,901 Shares of PepGen Inc. (NASDAQ:PEPG) StockJune 11, 2024 | businesswire.comPepGen Announces Executive Team PromotionsMay 22, 2024 | finance.yahoo.comWe're Not Very Worried About PepGen's (NASDAQ:PEPG) Cash Burn RateJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 20, 2024 | seekingalpha.comThe Prognosis For PepGenMay 15, 2024 | markets.businessinsider.comBuy Rating on PepGen Inc. Backed by PGN-EDO51’s Efficacy and Safety ProfileMay 14, 2024 | msn.comPEPG Stock Earnings: PepGen Beats EPS for Q1 2024May 14, 2024 | globenewswire.comPepGen Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 9, 2024 | msn.comHHS panel to vote in Nov. on DMD screening for newbornsMay 2, 2024 | markets.businessinsider.comBuy Rating on Sarepta Therapeutics Backed by Elevidys’s Market Expansion and FDA Approval ProspectsApril 26, 2024 | markets.businessinsider.comOptimistic Outperform Rating on Sarepta Therapeutics Amid Strong Elevidys Demand and Potential Label ExpansionApril 12, 2024 | insidermonkey.comHedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and MoreMarch 13, 2024 | marketwatch.comPepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease DesignationsSee More Headlines Receive PEPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PepGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PEPG CUSIPN/A CIK1835597 Webwww.pepgen.com Phone781-797-0979FaxN/AEmployees64Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$26.00 Low Stock Price Target$20.00 Potential Upside/Downside+24.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.32% Return on Assets-46.14% Debt Debt-to-Equity RatioN/A Current Ratio15.78 Quick Ratio15.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.55 per share Price / Book4.08Miscellaneous Outstanding Shares32,420,000Free Float30,926,000Market Cap$601.39 million OptionableNot Optionable Beta1.73 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. James G. McArthur Ph.D. (Age 62)President, CEO, Treasurer, Secretary & Director Comp: $834.98kMr. Noel P. Donnelly M.B.A. (Age 54)Chief Financial Officer Comp: $650.17kMr. Niels Svenstrup Ph.D. (Age 54)Senior Vice President of Chemistry, Manufacturing & Control Comp: $455.15kDr. Michael Gait Ph.D.Founder & Scientific Advisory Board MemberMs. Emiko BryantChief of StaffMr. Kyle BreidenstineVP of Finance & ControllerMore ExecutivesKey CompetitorsProtagonist TherapeuticsNASDAQ:PTGXDeciphera PharmaceuticalsNASDAQ:DCPHRocket PharmaceuticalsNASDAQ:RCKTMaravai LifeSciencesNASDAQ:MRVICatalyst PharmaceuticalsNASDAQ:CPRXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 13,397 shares on 7/26/2024Ownership: 0.136%Michelle L. MellionSold 7,571 sharesTotal: $136,732.26 ($18.06/share)Michelle L. MellionSold 12,625 sharesTotal: $229,775.00 ($18.20/share)Michelle L. MellionSold 5,901 sharesTotal: $106,218.00 ($18.00/share)Michelle L. MellionSold 3,288 sharesTotal: $59,315.52 ($18.04/share)View All Insider TransactionsView All Institutional Transactions PEPG Stock Analysis - Frequently Asked Questions How have PEPG shares performed this year? PepGen's stock was trading at $6.80 at the beginning of 2024. Since then, PEPG stock has increased by 172.8% and is now trading at $18.55. View the best growth stocks for 2024 here. How were PepGen's earnings last quarter? PepGen Inc. (NASDAQ:PEPG) posted its earnings results on Tuesday, May, 14th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.11. When did PepGen IPO? PepGen (PEPG) raised $126 million in an initial public offering on Friday, May 6th 2022. The company issued 9,000,000 shares at $13.00-$15.00 per share. Who are PepGen's major shareholders? Top institutional investors of PepGen include Bank of New York Mellon Corp (0.14%). Insiders that own company stock include Ra Capital Management, LP, James G Mcarthur, Jaya Goyal, Michelle L Mellion and Niels Svenstrup. View institutional ownership trends. How do I buy shares of PepGen? Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PEPG) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
